お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
980222

潰瘍性大腸炎:2029年までの世界の薬剤予測と市場分析

Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2029

出版日: | 発行: GlobalData | ページ情報: 英文 168 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円
潰瘍性大腸炎:2029年までの世界の薬剤予測と市場分析
出版日: 2020年12月31日
発行: GlobalData
ページ情報: 英文 168 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の潰瘍性大腸炎(UC)市場における成長の主な成長要因には、予測期間中の10件およぶ新しいパイプライン療法の開始と、主要8か国における診断された症例件数の増加が挙げられます。現在のUC市場は、軽度から中等度の疾患を対象とした安価なジェネリック医薬品、抗腫瘍壊死因子(TNF)や抗インテグリンなどの高価なバイオ製剤、重度の疾患を対象とした短期または長期の手術代替品として使用されるバイオシミラーなどで過密状態にあります。

また、同市場の成長に対する主な障壁として、競争が激しく混雑した市場だけでなく、その後のバイオシミラー発売に伴う主要バイオブランドの特許満了などが挙げられます。

当レポートは、世界の潰瘍性大腸炎(UC)市場について調査しており、疫学、病因、病態生理学、症状、診断、および治療ガイドラインを含むUCの概要、市場収益、治療の年間コスト、および予測期間における主要パイプライン製品の売上高、市場の成長および抑制要因などの情報を提供しています。

目次

第1章 目次

  • 表のリスト
  • 図のリスト

第2章 潰瘍性大腸炎:エグゼクティブサマリー

  • 2019年~2029年のUC市場における大幅な成長見通し
  • 競合とバイオシミラーの脅威によるUC市場の定義
  • パイプライン製品によるアンメットニーズへの部分的な対応
  • 重度/劇症患者を管理する機会
  • UC市場の成長を促進するための皮下バイオ製剤および経口療法
  • 医師と支払者の見解

第3章 イントロダクション

  • 影響
  • 関連レポート
  • 今後の関連レポート

第4章 病気の概要

  • 病因と病態生理学
  • 分類またはステージングシステム
  • 症状
  • 生活の質

第5章 疫学

  • 病気の背景
  • 危険因子と併存疾患
  • 世界および過去の動向
  • 予測調査手法
  • UCの疫学予測(2019-2029)
  • 討論

第6章 疾病管理

  • 診断と治療の概要
  • 治療の概要
  • 治療ガイドラインと主要処方薬
  • 米国
  • EU5ヵ国
  • 日本
  • カナダ

第7章 競合の評価

  • 概要
  • COVID-19の影響に関するKOLと支払人の見解

第8章 アンメットニーズと機会の評価

  • 概要
  • 安全で効果的な代替治療法の欠如
  • 重度/劇症患者の医療管理の改善
  • 治療と予後に対する反応性を予測するためのバイオマーカー
  • 患者から報告された結果の標準化

第9章 パイプライン評価

  • 概要
  • 臨床開発における有望な薬剤

第10章 現在および将来の企業

  • 概要
  • 企業戦略の動向
  • Johnson & Johnson
  • AbbVie
  • Takeda
  • Pfizer
  • Eli Lilly
  • EA Pharma
  • Galapagos
  • Bristol-Myers Squibb
  • Arena Pharmaceuticals

第11章 市場の見通し

  • 世界の市場
  • 米国
  • EU5ヵ国
  • 日本
  • カナダ

第12章 付録

  • 参考文献
  • 略語
  • 調査手法
  • 1次調査:当レポートでインタビューされたKOLと支払人
  • 1次調査:処方者調査
  • 著者について
  • GlobalDataについて
  • お問い合わせ
  • 免責事項
図表

List of Tables

List of Tables

  • Table 1: UC: Key Metrics in the 8MM
  • Table 2: Truelove and Witts Categorization of Disease Severity and Clinical Parameters
  • Table 3: Montreal Classification for the Distribution of UC
  • Table 4: Typical Symptoms of UC
  • Table 5: Risk Factors and Comorbidities for UC and IBD
  • Table 6: Guidelines Used for Managing UC
  • Table 7: Country Profile - US
  • Table 8: Country Profile - 5EU
  • Table 9: Country Profile - Japan
  • Table 10: Country Profile - Canada
  • Table 11: Leading Treatments for UC, 2020
  • Table 12: Johnson & Johnson's Disease Portfolio Assessment, 2020
  • Table 13: AbbVie's Disease Portfolio Assessment, 2020
  • Table 14: Takeda's Disease Portfolio Assessment, 2020
  • Table 15: Pfizer's Disease Portfolio Assessment, 2020
  • Table 16: Eli Lilly's Disease Portfolio Assessment, 2020
  • Table 17: EA Pharma's Disease Portfolio Assessment, 2020
  • Table 18: Galapagos' Disease Portfolio Assessment, 2020
  • Table 19: Bristol-Myers Squibb's Disease Portfolio Assessment, 2019
  • Table 20: Arena's Disease Portfolio Assessment, 2020
  • Table 21: Disease UC Market - Global Drivers and Barriers, 2019-2029
  • Table 22: Key Events Impacting Sales for Disease UC in the US, 2019-2029
  • Table 23: Disease UC Market - Drivers and Barriers in the US, 2019-2029
  • Table 24: Key Events Impacting Sales for Disease UC in the 5EU, 2019-2029
  • Table 25: Disease UC Market - Drivers and Barriers in the 5EU, 2019-2029
  • Table 26: Key Events Impacting Sales for Disease UC in Japan, 2019-2029
  • Table 27: Disease UC Market - Drivers and Barriers in Japan, 2019-2029
  • Table 28: Key Events Impacting Sales for Disease UC in Canada, 2019-2029
  • Table 29: UC Market -Drivers and Barriers in Canada, 2019-2029
  • Table 30: Key Historical and Projected Launch Dates for UC
  • Table 31: Key Historical and Projected Patent Expiry Dates for UC
  • Table 32: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: Global Sales Forecast by Country for Ulcerative Colitis in 2019 and 2029
  • Figure 2: Analysis of the Company Portfolio Gap in UC During the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of UC During the Forecast Period
  • Figure 4: Cellular Mechanisms Involved in the Pathogenesis of UC
  • Figure 5: Types of UC
  • Figure 6: 8MM, Diagnosed Incidence of UC, Men and Women, Cases per 100,000 Population, All Ages, 2019
  • Figure 7: 8MM, Diagnosed Prevalence of UC, Men and Women, %, All Ages, 2019
  • Figure 8: 8MM, Total Prevalence of UC, Men and Women, %, All Ages, 2019
  • Figure 9: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of UC
  • Figure 10: 8MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of UC
  • Figure 11: 8MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of UC
  • Figure 12: 8MM, Sources Used to Forecast the Post-Operative UC Cases Among Diagnosed Prevalent Cases of UC
  • Figure 13: 8MM, Sources Used to Forecast the Severity of Diagnosed Prevalent Cases of UC for Ages <18 years
  • Figure 14: 8MM, Diagnosed Incident Cases of UC, N, Both Sexes, All Ages, 2019
  • Figure 15: 8MM, Diagnosed Incident Cases of UC by Age, N, Both Sexes, 2019
  • Figure 16: 8MM, Diagnosed Incident Cases of UC by Sex, N, All Ages, 2019
  • Figure 17: 8MM, Diagnosed Prevalent Cases of UC, N, Both Sexes, All Ages, 2019
  • Figure 18: 8MM, Diagnosed Prevalent Cases of UC by Age, N, Both Sexes, 2019
  • Figure 19: 8MM, Diagnosed Prevalent Cases of UC by Sex, N, All Ages, 2019
  • Figure 20: 8MM, Diagnosed Prevalent Cases of UC by Severity, N, Ages <18 years, 2019
  • Figure 21: 8MM, Diagnosed Prevalent Cases of UC by Severity, N, Ages ≥18 Years, 2019
  • Figure 22: 8MM, Post-Operative UC Cases Among Diagnosed Prevalent Cases of UC, 2019
  • Figure 23: 8MM, Total Prevalent Cases of UC, N, Both Sexes, All Ages, 2019
  • Figure 24: 8MM, Total Prevalent Cases of UC by Age, N, Both Sexes, 2019
  • Figure 25: 8MM, Total Prevalent Cases of UC by Sex, N, All Ages, 2019
  • Figure 26: UC Treatment Algorithm
  • Figure 27: Unmet Need and Opportunity in UC, 2020
  • Figure 28: Overview of the Development Pipeline in UC
  • Figure 29: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for UC in the 8MM During the Forecast Period
  • Figure 30: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of UC During the Forecast Period
  • Figure 31: Analysis of the Company Portfolio Gap in UC During the Forecast Period
  • Figure 32: Global (8MM) Sales Forecast by Country for UC in 2019 and 2029
  • Figure 33: Global (8MM) Sales Forecast by Class for UC in 2019 and 2029
  • Figure 34: Sales Forecast by Class for UC in the US in 2019 and 2029
  • Figure 35: Sales Forecast by Class for UC in the 5EU in 2019 and 2029
  • Figure 36: Sales Forecast by Class for UC in Japan in 2019 and 2029
  • Figure 37: Sales Forecast by Class for UC in Canada in 2019 and 2029
目次
Product Code: GDHC205PIDR

Ulcerative colitis (UC) is a type of inflammatory bowel disease. In UC, chronic inflammation affects the colon (also known as the large intestines). Initially, UC usually manifests in the terminal part of the colon, the rectum, and is termed ulcerative proctitis. It can extend to the entire left part of the colon (left-sided proctitis) or the entire colon (pancolitis). The current UC market is overcrowded with cheap generic drugs for mild to moderate disease, expensive biologics such as anti-tumor necrosis factors (TNFs) and anti-integrins, and biosimilars for severe disease that are used as short- or long-term alternatives to surgical options. The R&D within this space consists of 10 late-stage pipeline drugs with five oral formulations, more convenient dosing frequencies, novel mechanisms of action (MOAs), and improved safety profiles and drug availability. However, the pipeline products will be challenged by the increasing emergence of biosimilars, since the major brands will experience patent cliffs throughout the forecast period. Furthermore, all but one drug are being developed for moderate to severe UC, which will result in a crowded market.

This model covers the market forecast for the marketed and late-stage pipeline UC therapeutics. The model segments patients by severity, with mild-moderate, moderate-severe, and severe/fulminant segments. The base year of this model is 2019, and the forecast period is 2020-2029.

KEY QUESTIONS ANSWERED

  • Which unmet needs are limiting the treatment of ulcerative colitis in the 8MM?
  • What strategies can the pharmaceutical industry employ to increase treatment rates for ulcerative colitis? How should these strategies differ across different geographical markets?
  • What effect will the launch of biosimilars and generics have on the sales of branded agents?
  • What are the main R&D trends in the ulcerative colitis market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?

Key Highlights

  • The greatest drivers of growth in the global UC market include the launch of 10 new pipeline therapies during the forecast period and an increasing diagnosed prevalence in many 8MM countries.
  • The main barriers to growth in the UC market include the crowded and competitive market as well as patent expiration of key biologic brands with subsequent biosimilar launch.
  • Novel drug classes in the UC pipeline include IL-23 inhibitors and S1P receptor modulators. In addition, Takeda will launch a subcutaneous version of their product, Entyvio, and two additional JAK inhibitors are expected to make their appearance on the market.
  • The most important unmet needs in the UC market are for safer and more effective therapies, an improvement in management of fulminant patients, biomarkers to predict responsiveness to therapy, and standardization of patient-reported outcomes.

Scope

  • Overview of UC including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline UC market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting UC therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global UC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global UC therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global UC market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global UC therapeutics market from 2019-2029.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Ulcerative Colitis: Executive Summary

  • 2.1 Large Growth is Expected for UC Market from 2019-2029
  • 2.2 Competition and Biosimilar Threat Defines UC Market
  • 2.3 Pipeline Products Partially Address Unmet Needs
  • 2.4 Opportunities for Managing Severe/Fulminant Patients Remain
  • 2.5 Subcutaneous Biologics and Oral Therapies to Drive Growth in UC Market
  • 2.6 What Do Physicians and Payers Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
  • 4.2 Classification or Staging Systems
  • 4.3 Symptoms
  • 4.4 Quality of Life

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
  • 5.5 Epidemiological Forecast for UC (2019-2029)
  • 5.6 Discussion

6 Disease Management

  • 6.1 Diagnosis and Treatment Overview
  • 6.2 Treatment Overview
  • 6.3 Treatment Guidelines and Leading Prescribed Drugs
  • 6.4 US
  • 6.5 5EU
  • 6.6 Japan
  • 6.7 Canada

7 Competitive Assessment

  • 7.1 Overview
  • 7.2 KOL and Payer Opinion on the Impact of COVID-19

8 Unmet Needs and Opportunity Assessment

  • 8.1 Overview
  • 8.2 Lack of Safe and Efficacious Treatment Alternatives
  • 8.3 Improved Medical Management for Severe/Fulminant Patients
  • 8.4 Biomarkers to Predict Responsiveness to Therapy and Prognosis
  • 8.5 Standardization of Patient-Reported Outcomes

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising Drugs in Clinical Development

10 Current and Future Players

  • 10.1 Overview
  • 10.2 Trends in Corporate Strategy
  • 10.3 Johnson & Johnson
  • 10.4 AbbVie
  • 10.5 Takeda
  • 10.6 Pfizer
  • 10.7 Eli Lilly
  • 10.8 EA Pharma
  • 10.9 Galapagos
  • 10.10 Bristol-Myers Squibb
  • 10.11 Arena Pharmaceuticals

11 Market Outlook

  • 11.1 Global Markets
  • 11.2 US
  • 11.3 5EU
  • 11.4 Japan
  • 11.5 Canada

12 Appendix

  • 12.1 Bibliography
  • 12.2 Abbreviations
  • 12.3 Methodology
  • 12.4 Primary Research - KOLs and Payers Interviewed for This Report
  • 12.5 Primary Research - Prescriber Survey
  • 12.6 About the Authors
  • 12.7 About GlobalData
  • 12.8 Contact Us
  • 12.9 Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.